Americans are struggling to afford Ozempic, even with insurance
published Thursday
found that among patients who were prescribed GLP-1 medications for diabetes, those who had higher copay costs were less likely to still be on the medication after a year compared to those with a lower copays. The study analyzed information from more than 90,000 adults prescribed GLP-1 drugs or or another new type of medication for their diabetes, to see who consistently took the medications. It found that those who had to pay $50 or more each month were 50% less likely to keep taking the medications compared to those who paid less than $10.
The researchers looked at information between 2014 and 2020, a time before GLP-1 medications were approved for weight loss. As interest in the medications grows, whether or not Americans can afford them could determine how effective they are. Especially after a
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Father’s Day gift guide according to budgetOur favourite gifts under $20, $50, $100 and $200
Read more »
FDA warns consumers not to use off-brand versions of Ozempic, WegovyThe U.S. Food and Drug Administration is warning consumers not to use versions of the popular weight-loss drug used in Ozempic and Wegovy and sold online because they might not contain the same ingredients as prescription products and may not be safe o...
Read more »
‘Ozempic Butt’ is becoming a problem for some trying to lose weight with popular drugFirst there was 'Ozempic Face' and now, apparently, there is 'Ozempic Butt.'
Read more »
Ozempic and Wegovy force weight loss companies to upend their approachesThe growing popularity of obesity and diabetes drugs Wegovy and Ozempic is inspiring other weight-loss companies to fundamentally shift their business models.
Read more »
A castle in Scotland is up for sale for $37,000 – but beware a bargainInsider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Read more »